Drug intelligence / Profile preview

626

Development stage: Phase 2
Lead developer: 3S Guojian Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

626 is an investigational drug currently being evaluated in clinical trials. It is being studied for its efficacy and safety in patients with Systemic Lupus Erythematosus (SLE), where it is administered in conjunction with standard of care therapy. Additionally, a specific formulation or variant, SSGJ-626, is undergoing a Phase I clinical study in healthy adult subjects to assess its safety, tolerability, pharmacokinetics (PK), and immunogenicity following a single subcutaneous injection.

Brand names: SSGJ-626SSGJ626SSGJ 626
Other names: 626Recombinant anti-BDCA2 humanized monoclonal antibody

Targets

CLEC4C (C-type lectin domain family 4 member C)

Beyond the preview

Go deeper on 626.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 626.

Explore the full profile